Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.

Journal Article (Journal Article;Review)

Radionuclides which decay by the emission of alpha-particles are attractive for certain radioimmunotherapeutic applications. These include the treatment of lymphomas, compartmentally spread malignancies such as ovarian cancer and neoplastic meningitis, and micrometastatic disease. Two alpha-emitting radionuclides of interest for this purpose are 212Bi (60.6 min half life) and 211At (7.2 hr half life). Compared with the beta-emitters commonly used for radiotherapy, the alpha-particles of 212Bi and 211At are of higher energy, much shorter range (less than 100 microm), and considerably higher linear energy transfer. Preliminary results obtained in a variety of in vitro systems and in vivo models have documented the exquisite toxicity of alpha-particles and have established a basis for initiating radiotherapy trials in humans with monoclonal antibodies labeled with alpha-emitting radionuclides.

Full Text

Duke Authors

Cited Authors

  • Zalutsky, MR; Bigner, DD

Published Date

  • 1996

Published In

Volume / Issue

  • 35 / 3

Start / End Page

  • 373 - 379

PubMed ID

  • 8679269

International Standard Serial Number (ISSN)

  • 0284-186X

Digital Object Identifier (DOI)

  • 10.3109/02841869609101654


  • eng

Conference Location

  • England